Entera Appoints Ramesh Ratan as Chief Financial Officer
April 15, 2021 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Israel, April 15, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the...
New Data Suggest Entera’s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress
April 06, 2021 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, April 06, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will...
Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020
March 18, 2021 08:00 ET
|
Entera Bio Ltd.
‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒‒ Final Data, Including Bone Mineral Density, Expected in Q2:21 ‒‒ FDA Approval of EB613 IND for the Treatment of Osteoporosis Enables...
Entera Bio to Report Financial Results for the Year Ended December 31, 2020 on March 18, 2021
March 11, 2021 16:15 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report...
Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data
March 11, 2021 08:30 ET
|
Entera Bio Ltd.
‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒‒ Final Analysis of 6-Month Data, Including Change in Bone Mineral Density, Expected in Q2:21 ‒ ...
Entera Bio To Present At The H.C. Wainwright Global Life Sciences Conference
March 04, 2021 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 04, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its...
Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research
February 25, 2021 08:30 ET
|
Entera Bio Ltd.
‒ EB612 When Added to Standard of Care Led to a Statistically Significant Decrease in Supplemental Calcium Usage – ‒ Oral Human Parathyroid Hormone (1-34) Has the Potential to Have a Major Impact on...
Entera Bio Initiates New Research Program For Oral GLP-2
February 08, 2021 08:30 ET
|
Entera Bio Ltd.
‒ Program Leverages Entera’s Platform for Potential Development of Oral GLP-2 Analogs for Gastrointestinal and Other Indications ‒‒ GLP-2 Analogs Currently Administered Via Daily Injection to Treat...
Entera Bio Issues Letter to Shareholders
January 11, 2021 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to...
Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis
December 10, 2020 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that the...